GDF2026 - Controlled Correspondences: Minimizing Rejections, Maximizing Results
Generic Drugs Forum (Office of Generic Drugs) · July 30, 2026
FDA Office of Generic Drugs presentation on best practices for controlled correspondence in ANDA development, including timelines (90% responses for level 1 within 60 days, level 2 within 120 days), submission formatting, sample handling, letters of authorization, and clarification limits; Dr. Zink was introduced as the next speaker.
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.
No transcript available.
No outline available for this source.
No related articles available for this source.
No highlights available for this source.
No claims available for this source.
No actions available for this source.
No topics available for this source.
No clarifying details available for this source.
No discussions available for this source.
No community relevance data available for this source.
No funding sources available for this source.
No speakers available for this source.
No transcript available for this source.